This study adds to growing evidence that GLP-1 receptor agonists have a positive effect on mental health, and thus could be a particularly good treatment option for patients with obesity and/or T2D with comorbid psychiatric illness. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.